GILEAD SCIENCES, INC. Equity Securities, FV-NI, Gain (Loss)
GILEAD SCIENCES, INC. (GILD) reported Equity Securities, FV-NI, Gain (Loss) of $343.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiGainLoss · last filed 2026-08-06
- GILEAD SCIENCES, INC. equity securities, fv-ni, gain (loss) for the quarter ending 2026-06-30 was $343.00M, a 141.55% increase year-over-year.
- GILEAD SCIENCES, INC. equity securities, fv-ni, gain (loss) for the quarter ending 2026-03-31 was $142.00M.
- GILEAD SCIENCES, INC. equity securities, fv-ni, gain (loss) for the quarter ending 2025-12-31 was $253.00M.
- GILEAD SCIENCES, INC. equity securities, fv-ni, gain (loss) for the quarter ending 2025-09-30 was $483.00M, a 87.21% increase year-over-year.
- GILEAD SCIENCES, INC. equity securities, fv-ni, gain (loss) for fiscal 2025 was $451.00M.
- GILEAD SCIENCES, INC. equity securities, fv-ni, gain (loss) for fiscal 2024 was -$274.00M.
- GILEAD SCIENCES, INC. equity securities, fv-ni, gain (loss) for fiscal 2023 was -$167.00M.
- GILEAD SCIENCES, INC. equity securities, fv-ni, gain (loss) for fiscal 2022 was -$657.00M.
| Period end | Equity Securities, FV-NI, Gain (Loss) 3 month | Equity Securities, FV-NI, Gain (Loss) 6 month | Equity Securities, FV-NI, Gain (Loss) 9 month | Equity Securities, FV-NI, Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $343.00M 10-Q · filed 2026-08-06 | $485.00M 10-Q · filed 2026-08-06 | $738.00M derived: sum of 3 quarters · filed 2026-08-06 | $1.22B derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $142.00M 10-Q · filed 2026-05-07 | $395.00M derived: sum of 2 quarters · filed 2026-05-07 | $878.00M derived: sum of 3 quarters · filed 2026-05-07 | $1.02B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $253.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $736.00M derived: sum of 2 quarters · filed 2026-02-24 | $878.00M derived: sum of 3 quarters · filed 2026-08-06 | $451.00M 10-K · filed 2026-02-24 |
| 2025-09-30 | $483.00M 10-Q · filed 2025-11-07 | $625.00M derived: sum of 2 quarters · filed 2026-08-06 | $198.00M 10-Q · filed 2025-11-07 | $73.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $142.00M 10-Q · filed 2026-08-06 | -$284.00M 10-Q · filed 2026-08-06 | -$410.00M derived: sum of 3 quarters · filed 2026-08-06 | -$152.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$426.00M 10-Q · filed 2026-05-07 | -$552.00M derived: sum of 2 quarters · filed 2026-05-07 | -$294.00M derived: sum of 3 quarters · filed 2026-05-07 | -$686.00M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$126.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $132.00M derived: sum of 2 quarters · filed 2026-02-24 | -$260.00M derived: sum of 3 quarters · filed 2026-02-24 | -$274.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | $258.00M 10-Q · filed 2025-11-07 | -$134.00M derived: sum of 2 quarters · filed 2025-11-07 | -$148.00M 10-Q · filed 2025-11-07 | |
| 2024-06-30 | -$392.00M 10-Q · filed 2025-08-07 | -$405.00M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | -$14.00M 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | -$167.00M 10-K · filed 2026-02-24 | |||
| 2022-12-31 | -$657.00M 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |